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Abstract The synthesis and biological activity of a hith-
erto unknown class of compounds, the imidazolylthiazoli-
din-4-ones, are described. A two-step procedure has been
elaborated starting from our previously described 2-ami-
noimidazoles. The application of microwave irradiation has
been proven to be beneficial for the condensation of the imine
with mercaptoacetic acid leading to the formation of imidaz-
olylthiazolidin-4-ones. None of the compounds showed anti-
viral activity at subtoxic concentrations. Several compounds
displayed a moderate cytostatic activity. These data form the
basis for further improvement of the potential antiprolifera-
tive activity of this class of compounds.
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Introduction
The synthesis of the thiazolidin-4-one scaffold is gaining
considerable attention due to the fact that its derivatives have
shown a wide spectrum of activities like antifungal [1,2],
antibacterial [3,4], anticonvulsant [5,6], COX-1 inhibitors
[7], anticancer [8], antituberculosis [9–11], and antihista-
minic [12] activity (Fig. 1). Some thiazolidin-4-ones are
reported as human immunodeficiency virus-1 (HIV-1) non-
nucleoside reverse transcriptase inhibitors (NNRTIs) [13,14]
which are selective inhibitors of the reverse transcriptase en-
zyme of HIV-1 and do not inhibit HIV-2 or human cellular
DNA polymerases [15,16].
Presently, four NNRTIs, namely nevirapine, delavirdine,
efavirenz, and etravirine are available in clinical practice.
Combination of these drugs with nucleoside reverse trans-
criptase inhibitors and protease inhibitors leads to a decrease
of viral load in most of the HIV-infected patients. How-
ever, there is a significant emergence of resistance to cur-
rent drugs. Consequently, the synthesis of novel antiviral
agents, which are also effective against mutant HIV strains,
remains a high priority for researchers. Thiazolidin-4-ones
are structurally related to 1-aryl-1H,3H-thiazolo[3,4-a]benz-
imidazoles (TBZs) which are highly active NNRTIs [13,14].
Other thiazolidin-4-ones are also reported containing substi-
tutions like thiazoles, benzthiazoles, benzimidazoles, pyri-
dines, pyrimidines, etc., at N-3 (Fig. 2). It can be seen from
these examples that anti-HIV activity of thiazolidin-4-ones is
strongly dependent on the nature of the substituent at C-2 and
N-3 of the thiazolidin-4-one ring [13,14,17,18]. Particularly,
high activity was observed for the compounds bearing a 2,6-
dihalophenyl at C-2 and a heterocyclic ring at N-3 (Fig. 2).
During the last 2 years many 2-aminoimidazole-based ma-
rine sponge alkaloids and structural analogues have been
shown to possess inhibitory activity against proteobacteri-
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Fig. 2 Structure of TBZs, N-3 substituted thiazolidinones, and
imidazolylthiazolidin-4-ones
al biofilms [19–21]. Most of these biologically active com-
pounds are characterized by a 1-substituted or 1-unsubsti-
tuted 2-aminoimidazole subunit bearing alkyl and/or aryl
substituents. However, only a few synthetic procedures are
giving access to the diversely substituted 2-aminoimidazoles.
We have recently proposed some new microwave-assisted
[22–24] approaches for the synthesis of libraries of 2-amino-
imidazole derivatives [25,26]. Therefore, we decided that it
would be interesting to apply the synthesized 2-aminoimi-
dazole derivatives to generate hitherto unknown imidazolyl-
thiazolidin-4-ones.
Results and discussion
Chemistry
The synthesis of 2-aminoimidazoles was carried out accord-
ing to the previously published work from our group [25,26].
Initially, we tried out a one-pot synthesis of the title com-
pound according to the procedure described by Barreca et
al. [13,14]. However, upon refluxing a mixture of 1-methyl-
5-phenyl-1H-imidazol-2-amine (1a), 2,5-dichlorobenzalde-
hyde (2a) and mercaptoacetic acid 3 in toluene for 8 h, only
traces of the desired compound were obtained along with
the starting materials and some unidentified by-products
(Scheme 1). Similar results were obtained when the reaction
was carried out using microwave irradiation (sealed vials) at
a ceiling temperature of 120 ◦C for 30 min. As the release of
water during the imine formation might hamper the product
formation, the reaction was performed using a Dean–Stark
water separator, however, with little success.
After a careful investigation of the reaction mixture by
mass analysis we found that the imine formation was the
problematic step. Therefore, we decided to investigate a two-
step procedure. Refluxing the 2-aminoimidazole 1a and 2,6-
dichlorobenzaldehyde (2a) in dry toluene using 5 mol% of
Yb(OTf)3 as catalyst, the corresponding imine 5a could be
isolated in 82% yield. It is noteworthy that when this reac-
tion was performed under microwave irradiation it did not
run to completion and more impurities were formed com-
pared to conventional heating. After having synthesized sev-
eral imines applying this procedure, we started to investigate
the synthesis of the corresponding imidazolylthiazolidin-4-
ones 4. When a mixture of the imine 5a and 1.5 equiv of
mercapto acetic acid (3) in toluene was refluxed during 6 h,
only a minor amount of the desired product 4a could be iso-
lated due to extensive degradation of the starting imine 5a
during reaction (Table 1, entry 1). As the release of water
during the condensation might hamper the product forma-
tion, the reaction was performed using a Dean–Stark water
separator, however with little success (Table 1, entry 2). The
reaction was also tried in ethanol at reflux temperature; how-
ever, extensive degradation of the imine was observed result-
ing in no product formation. (Table 1, entry 3).
Next, we investigated the reaction under microwave irra-
diation. First the reaction was evaluated in ethanol at a ceiling
temperature of 100 ◦C for 20 min giving very small amount
of product (Table 1, entry 4). When the reaction was carried
out in toluene at 110 ◦C for 20 min, 18% of the desired prod-
uct was present in the crude reaction mixture according to
GC-MS analysis (Table 1, entry 5). The best conditions were
found to be 2.0 equiv of mercaptoacetic acid (3) in 3 mL
of toluene using 100 W maximum power at a ceiling tem-
perature of 120 ◦C for 30 min. The desired product could be
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Scheme 1 Attempts for the one-pot three-component synthesis of imidazolylthiazolidin-4-ones
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Table 1 Optimization conditions for the synthesis of imidazolylthiazolidin-4-onea
N
N
N
ClCl
HOOC
SH
5a 3
N
N
N
ClCl
S
O
Conditions
4a
Entry Mercaptoacetic acid 3 (equiv) Solvent (mL) T or MWb Temp (◦C) Time Ratioc 4a:5a:1a
1 1.5 Toluene (5) T Reflux 6.0 h 5:30:55
2d 1.5 Toluene (5) T Reflux 6.0 h 7:35:50
3 1.5 Ethanol (5) T Reflux 4.0 h 0:5:75
4 1.5 Ethanol (3) MW 100 ◦C 20 min 8:10:65
5 1.5 Toluene (3) MW 110 ◦C 20 min 18:30:45
6 2.0 Toluene (3) MW 120 ◦C 30 min 31e:0:40
7 2.0 Toluene (3) MW 140 ◦C 30 min 16:0:27
a Reaction were run on a 0.3 mmol scale of 5a. b The reaction mixture was irradiated at 100 W maximum power. c Ratios were determined by
GC-MS analysis. d Reaction carried out in a Dean–Stark water separator. e Isolated yield (single run). Bold values indicate the best/optimized
condition
isolated in 31% yield (Table 1, entry 6). Increasing the tem-
perature to 140 ◦C resulted in the formation of only 16%
product and other unidentified by-products. The relatively
low yield could be rationalized in all the cases by the fact
that the imine was degraded to the corresponding amine 1 and
aldehyde 2 at more or less extent. A small library of imidaz-
olylthiazolidin-4-one 4 was generated using the optimized
conditions, yielding the desired compounds in moderate to
good isolated yields (Table 2).
The structure of compound 4e was assigned by single crys-
tal X-ray diffraction (Fig. 3). The compound crystallized in
the chiral space group P21, with two molecules in the asym-
metric unit. As the compound contains a chiral center (on C14
and C34 for the first and second molecule in the asymmet-
ric unit, respectively), the absolute configuration was deter-
mined as (R) and (S) for C14 and C34, respectively. Hence
both enantiomers are present in the structure.
Biological results
All the final compounds were screened for broad-spectrum
antiviral activity. The viral strains tested in this study con-
sisted of a variety of DNA and RNA viruses as listed under
the Experimental Methods Section. None of the compounds
showed antiviral activity at subtoxic (MCC) concentrations.
The compounds were also evaluated on their cytostatic activ-
ity against murine leukemia L1210 and human lymphocyte
CEM and Molt4/C8 tumor cell lines. The cytostatic activ-
ity varied widely depending on the nature of the compounds.
Whereas 4a, 4b, 4c, 4g, and 4i were virtually devoid of signif-
icant antiproliferative activity (IC50 > 50 µM), other com-
pounds such as 4d–4f, 4h, 4j, 4l, 4m, 4n, and 4o showed
a moderate cytostatic activity (IC50 range between 8.6 and
30 µM). The structure-activity relationship (SAR) is rather
unclear in terms of identifying the substituents that causes
the highest cytostatic activity. Both the presence of difluoro-,
dichloro- or fluoro-, chloro-substituents in X1 and X2 resulted
in compounds that have a comparable cytostatic activity (8.6–
14µM) (i.e., compare 4o, 4j, 4m, and 4h). However, substi-
tution of the phenyl moiety in R1 with a halogen (Cl, Br,
I) (compare 4d, 4e, 4f, 4l) is acceptable to keep the cyto-
static activity, whereas substitution with methoxy groups or a
methylthio group results in decreased antiproliferative activ-
ity (compare 4b, 4c, 4g and 4k). The substituent at the R2
position seems less critical for cytostatic activity. Therefore,
it would be of interest to expand the current series of com-
pounds with additional modifications on the R1 part of the
molecule to further improve the cytostatic potential of the
test compounds.
Conclusion
In conclusion, a two-step procedure has been developed for
the synthesis of novel class of compounds, imidazolylthiaz-
olidin-4-ones. The application of microwave irradiation has
been proven to be beneficial for the condensation of the
imine with mercaptoacetic acid. All the final compounds
were screened for broad-spectrum antiviral activity, cyto-
static activity against murine leukemia L1210, and human
lymphocyte CEM and Molt4/C8 tumor cell lines. None of
the compounds showed antiviral activity at subtoxic (MCC)
concentrations, but several compounds displayed a moderate
cytostatic activity which forms the base for the future work.
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Table 2 Synthesis of the imidazolylthiazolidin-4-ones (4b–o)
N
N
NH2
R2
R1
CHO
X2 X1
N
N
N
R2
R1
X2 X1
N
N
N
R2
R1
X2 X1
S
O
1 2a-c 5 4
Yb(OTf)3
Dry Toluene
Reflux
Dry Toluene
MW
30 min
Mercapto-
acetic acid 3
2a (X1, X2 = Cl)
2b (X1 = Cl, X2 = F)
2c (X1, X2 = F)
Entry Comp. R1 R2 X1 X2 Yielda (%) of 5 Yielda (%) of 4
1 4b 2,5-dimethoxyphenyl Me Cl Cl 78 23
2 4c 3,4-dimethoxyphenyl Me Cl Cl 66 20
3 4d Phenyl Et Cl Cl 78 21
4 4e 4-bromophenyl Et Cl Cl 38 37
5 4f 4-iodophenyl Et Cl Cl 62 63
6 4g 4-(methylthio)phenyl Me Cl Cl 85 36
7 4h Biphenyl Et Cl Cl 72 61
8 4i Phenyl Butyl Cl Cl 59 88
9 4j Phenyl Benzo[d][1,3]dioxol-5-ylmethyl Cl Cl 66 49
10 4k 3,4,5-trimethoxyphenyl Me Cl F 32 68
11 4l 4-chlorophenyl Et Cl F 35 50
12 4m Phenyl Cyclopentyl Cl F 62 32
13 4n Phenyl 4-methoxybenzyl Cl F 60 26
14 4o Phenyl Pentyl F F 25 24
a Isolated yields (single run)
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Fig. 3 X-ray crystal structure of compound 4e, with atom-labeling
scheme. Displacement ellipsoids are drawn at the 50% probability level.
CCDC 746983 contains the supplementary crystallographic data for this
structure 4e. These data can be obtained free of charge from the Cam-
bridge Crystallographic Data Center via www.ccdc.cam.ac.uk/conts/
retrieving.html
Table 3 Cytostatic activity of
the test compounds
a 50% Inhibitory concentration,
or compound concentration
required to inhibit tumor cell
proliferation by 50%
Compounds ICa50(µM)
L1210 Molt4/C8 CEM
4a 316 ± 61 336 ± 46 258 ± 23
4b 68 ± 29 65 ± 30 104 ± 39
4c >500 >500 >500
4d 17 ± 7 30 ± 4 26 ± 6
4e 17 ± 3 12 ± 2 16 ± 0
4f 16 ± 1 11 ± 0 20 ± 7
4g 77 ± 7 52 ± 11 71 ± 8
4h 13 ± 1 11 ± 1 14 ± 2
4i 266 ± 50 240 ± 18 232 ± 28
4j 8.7 ± 1.0 9.2 ± 0.4 13 ± 0
4k 47 ± 1 44 ± 1 55 ± 5
4l 14 ± 2 14 ± 5 30 ± 3
4m 9.1 ± 0.7 8.6 ± 1.0 12 ± 1
4n 15 ± 5 12 ± 2 19 ± 1
4o 8.6 ± 0.9 9.3 ± 3.5 12 ± 1
Experimental
General experimental methods
1H NMR spectra were recorded on a Bruker Avance 300 MHz
instrument using CDCl3or DMSO-d6 as solvent unless oth-
erwise stated. The 1H NMR and 13C chemical shifts are
reported in parts per million relative to tetramethylsilane us-
ing the residual solvent signal as an internal reference. Mass
spectra were recorded by using a Kratos MS50TC and a
Kratos Mach III system. The ion source temperature was
150–250 ◦C, as required. High-resolution electron impact
(EI) mass spectra were performed with a resolution of 10,000.
The low-resolution spectra were obtained with a HP5989A
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MS instrument. For, TLC, analytical TLC plates (Alu-gram
SIL G/UV254) and 70–230 mesh silica gel (E. M. Merck)
were used.
Microwave irradiation experiments
All microwave irradiation experiments were carried out in a
dedicated CEM-Discover monomode microwave apparatus,
operating at a frequency of 2.45 GHz with continuous irradi-
ation of 300 W maximum power. The reactions were carried
out in 10 mL glass tubes, sealed with a Teflon septum and
placed in the microwave cavity. Initially, microwave irradi-
ation of required watts was used and the temperature was
ramped from room temperature to the desired temperature.
Once this was reached the reaction mixture was held at this
temperature for the required time. The reaction mixture was
continuously stirred with magnetic stirring during the reac-
tion. The temperature was measured with an IR sensor on
the outer surface of the process vial. After the irradiation,
gas jet cooling cooled the reaction vessel rapidly to ambient
temperature.
Antiviral activity assays
The antiviral assays, other than the anti-HIV assays, were
based on inhibition of virus-induced cytopathicity in HEL
[herpes simplex virus type 1 (HSV-1) (KOS), HSV-2 (G),
vaccinia virus, vesicular stomatitis virus], Vero (parainflu-
enza-3, reovirus-1, Sindbis virus and Coxsackie B4), HeLa
(vesicular stomatitis virus, Coxsackie virus B4, and respira-
tory syncytial virus) or MDCK [influenza A (H1N1; H3N2)
and influenza B] cell cultures. Confluent cell cultures (or
nearly confluent for MDCK cells) in microtiter 96-well plates
were inoculated with 100 CCID50 of virus (1 CCID50 being
the virus dose to infect 50% of the cell cultures). After a 1 h
virus adsorption period, residual virus was removed, and the
cell cultures were incubated in the presence of varying con-
centrations (200, 40, 8, …, µM) of the test compounds. Viral
cytopathicity was recorded as soon as it reached completion
in the control virus-infected cell cultures that were not treated
with the test compounds. The minimal cytotoxic concentra-
tion (MCC) of the compounds was defined as the compound
concentration that caused a microscopically visible alteration
of cell morphology. The methodology of the anti-HIV assays
was as follows: human CEM (∼ 3×105cells/cm3) cells were
infected with 100 CCID50 of HIV(IIIB) or HIV-2(ROD)/mL
and seeded in 200-µL wells of a microtiter plate containing
appropriate dilutions of the test compounds. After 4 days of
incubation at 37 ◦C, HIV-induced CEM giant cell formation
was examined microscopically.
Cytostatic/toxic activity assays
Murine leukemia L1210 and human lymphocyte CEM and
Molt4/C8 cells were seeded in 96-well microtiter plates at
50,000 (L1210) or 75,000 (CEM and Molt4/C8) cells per
200µL-well in the presence of different concentrations of the
test compounds. After 2 (L1210) or 3 (CEM and Molt4/C8)
days, the viable cell number was counted using a Coulter
counter apparatus. The 50% cytostatic concentration (CC50)
was defined as the compound concentration required to in-
hibit tumor cell proliferation by 50%.
General procedure for the preparation of 1a–o
General procedure for the preparation of 1a–o is the same
as previously described [25,26] by our group. Data for the
compounds 1a, 1b, 1d–g, 1i, and 1k–o are in accordance with
the previously published work [25,26].
5- (3,4 -Dimethoxyphenyl) -1 -methyl-1H-imidazol-2-amine
(1c). 69% yield. 1H NMR (300 MHz, DMSO-d6) δ 7.0–
6.85 (m, 3H), 6.49 (s, 1H), 5.50 (br, 2H), 3.78 (s, 3H), 3.76
(s, 3H), 3.34 (s, 3H). 13C NMR (75 MHz, DMSO-d6) δ 151.7,
149.7, 148.5, 128.7, 124.8, 122.9, 120.2, 113.0, 112.1, 56.4,
31.1. HRMS (EI): calcd for C12H15N3O2: 233.1164, found
233.1178.
5-[1,1′-biphenyl]-1-ethyl-1H-imidazol-2-amine (1h). 78%
yield. 1H NMR (300 MHz, CDCl3) δ 7.63 (m, 4H), 7.43 (m,
5H), 6.74 (s, 1H), 3.90 (q, J = 7.3 Hz, 2H), 3.69 (br, 2H),
1.31 (t, J = 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 149.3,
140.9, 140.5, 130.2, 129.3, 128.9, 127.8, 127.4, 123.5, 38.6,
15.5. HRMS (EI): calcd for C12H15N3O2: 263.1422, found
263.1432.
1- ((benzo[d][1,3]dioxol -6 -yl)methyl) -5 -phenyl -1H- imi-
dazol-2-amine (1j). 83% yield. 1H NMR (300 MHz, CDCl3)
δ 7.32 (m, 6H), 6.79 (m, 2H), 6.61 (s, 1H), 5.98 (s, 2H),
4.93 (s, 2H), 4.01 (br, 2H). 13C NMR (75 MHz, CDCl3)
δ 150.3, 147.7, 131.0, 130.6, 130.3, 129.2, 129.0, 128.3,
127.7, 123.6, 119.6, 109.2, 107.0, 46.7. HRMS (EI): calcd
for C17H15N3O2: 293.1164, found 293.1170.
General procedure for the preparation of 5a–o. 2-Amino
imidazole 1 (1 mmol), 2, 6-dihalo benzaldehyde 2 (1.2 mmol)
and ytterbium triflate (5 mol %) were successively added to
dry toluene (5 mL) and stirred at reflux temperature. After
completion of the reaction, solvent was removed under re-
duced pressure and residue was purified by flash column
chromatography (from 10 to 40% ethyl acetate in heptane)
to afford compounds 5a–o.
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N-(2,6 -Dichlorobenzylidene) -1 -methyl -5-phenyl-1H-imi-
dazol-2-amine (5a). Yellow solid, yield 82%, M.P. 122–
124 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.57 (s, 1H),
7.45–7.39 (m, 7H), 7.26 (m, 1H), 7.16 (s, 1H), 3.80 (s,
3H). 13C NMR (75 MHz, CDCl3): 154.8, 150.5, 136.1,
134.4, 131.6, 130.8, 130.0, 129.3, 128.8, 128.3, 127.9, 126.9,
30.7. HRMS (EI): calcd for C17H13N3Cl2: 329.0486, found:
329.0478.
N-(2,6 -dichlorobenzylidene) -5 - (2,5 -dimethoxyphenyl)-1-
methyl-1H-imidazol-2-amine (5b). Yellow solid, yield
78%, m.p. 156–158 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.56
(s, 1H), 7.40 (d, J = 8.22 Hz, 2H), 7.26 (t, J = 16.44, 8.11 Hz,
1H), 7.09 (s, 1H), 6.93 (s, 2H), 6.88 (s, 1H), 3.81 (s, 3H),
3.79 (s, 3H), 3.63 (s, 3H). 13C NMR (75 MHz, CDCl3):
154.5, 153.5, 151.4, 150.1, 136.0, 131.8, 130.6, 129.3, 127.4,
119.8, 117.5, 114.9, 112.1, 55.9, 30.4. HRMS (EI): calcd for
C19H17O2N3Cl2: 389.0698, found: 389.0704.
N-(2,6 -dichlorobenzylidene) -5 - (3,4 -dimethoxyphenyl)-1-
methyl-1H-imidazol-2-amine (5c). Yellow solid, yield 66%,
m.p. 147–150 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.55 (s,
1H), 7.41 (d, J = 7.32 Hz, 2H), 7.26 (t, J = 16.37, 8.10 Hz,
1H), 7.11 (s, 1H), 6.99–6.94 (m, 3H), 3.94 (s, 6H), 3.77
(s, 3H). 13C NMR (75 MHz, CDCl3): 154.5, 150.1, 149.0,
136.0, 134.3, 131.6, 130.7, 129.3, 126.4, 122.7, 121.1, 111.8,
111.3, 55.9, 30.6. HRMS (EI): calcd for C19H17O2N3Cl2:
389.0698, found: 389.0688.
N-(2,6-dichlorobenzylidene)-1-ethyl-5-phenyl-1H-imidazol-
2-amine (5d). Yellow solid, yield 78%, m.p. 103–105 ◦C,
1 H NMR (300 MHz, CDCl3): δ 9.59 (s, 1H), 7.47–7.40
(m, 6H), 7.28 (t, J = 16.40, 8.12 Hz, 1H), 7.12 (s, 1H), 4.29
– 4.22 (q, 2H), 1.33 (t, J = 14.61, 7.29 Hz, 3H). 13C NMR
(75 MHz, CDCl3): 155.1, 150.3, 136.5, 134.1, 132.1, 131.1,
130.6, 129.7, 128.9, 127.4, 38.8, 16.9. HRMS (EI): calcd for
C18H15N3Cl2: 343.0643, found: 343.06445.
N-(2,6 -dichlorobenzylidene)-5-(4-bromophenyl)-1-ethyl-1
H-imidazol-2-amine (5e). Yellow solid, yield 38%, m.p.
126–129 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.59 (s, 1H),
7.60 (d, J = 8.22 Hz, 2H), 7.41 (d, J = 8.22 Hz, 2H), 7.33–7.26
(m, 3H), 7.12 (s, 1H), 4.27–4.20 (q, 2H), 1.31 (t, J = 14.64,
7.32 Hz, 3H). 13C NMR (75 MHz, CDCl3): 155.6, 150.6,
136.5, 132.9, 131.2, 130.3, 129.7, 127.7, 122.7, 38.8, 16.9.
HRMS (EI): calcd for C18H14N3BrCl2: 420.9748, found:
420.9743.
N-(2,6 -dichlorobenzylidene) -1 -ethyl -5 - (4-iodophenyl)-1
H-imidazol-2-amine (5f). Yellow solid, yield 62%, m.p.
120–122 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.58 (s, 1H),
7.79 (d, J = 8.22 Hz, 2H), 7.40 (d, J = 8.22 Hz, 2H), 7.29–
7.12 (m, 4H), 4.27–4.20 (q, 2H), 1.31 (t, J = 14.64, 7.32 Hz,
3H). 13C NMR (75 MHz, CDCl3): 155.6, 150.6, 138.4, 136.5,
133.0, 132.0, 131.2, 130.5, 129.8, 127.7, 94.1, 38.8, 16.9.
HRMS (EI): calcd for C18H14N3ICl2: 468.9609, found:
468.9616.
N-(2,6 -dichlorobenzylidene) -1 -methyl -5 - (4-(methylthio)
phenyl)-1H-imidazol-2-amine (5g). Yellow solid, yield
85%, m.p. 88–90 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.56
(s, 1H), 7.42–7.26 (m, 7H), 7.15 (s, 1H), 3.79 (s, 3H), 2.53 (s,
3H). 13C NMR (75 MHz, CDCl3): 154.7, 150.4, 138.7, 136.0,
133.9, 131.5, 130.7, 129.3, 128.5, 126.8, 30.7, 15.5. HRMS
(EI): calcd for C18H15SN3Cl2: 375.0363, found: 375.0358.
N-(2,6-dichlorobenzylidene)-1-ethyl-5-[1,1′-biphenyl] -1H-
imidazol-2-amine (5h). Yellow solid, yield 72%, m.p. 147–
149 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.60 (s, 1H), 7.71–
7.63 (m, 4H), 7.54–7.40 (m, 7H), 7.29-7.25 (m, 1H), 7.18
(s, 1H), 4.34–4.27 (q, 2H), 1.37 (t, 14.61, 7.32 Hz, 3H). 13C
NMR (75 MHz, CDCl3): 155.2, 150.5, 141.2, 136.5, 133.8,
132.1, 129.8, 129.1, 128.0, 127.4, 38.9, 17.0. HRMS (EI):
calcd for C24H19N3Cl2: 419.0956, found: 419.0949.
N-(2,6-dichlorobenzylidene)-1-butyl-5-phenyl-1H-imidazol-
2-amine (5i). Yellowish gree solid, yield 59%, m.p. 98–
100 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.60 (s, 1H), 7.44–
7.39 (m, 7H), 7.28 –7.23 (m, 1H), 7.12 (s, 1H), 4.24–4.18
(q, 2H), 1.70–1.60 (m, 2H), 1.28–1.16 (m, 2H), 0.80 (t,
14.64, 7.32 Hz, 3H). 13C NMR (75 MHz, CDCl3): 154.6,
150.2, 136.1, 133.9, 131.6, 130.7, 129.3, 128.7, 128.0, 127.0,
43.2, 33.0, 19.8, 13.5. HRMS (EI): calcd for C20H19N3Cl2:
371.0956, found: 371.0961.
N-(2,6 -dichlorobenzylidene) -1 - (benzo[d][1,3]dioxol -5 -
ylmethyl)-5-phenyl-1H-imidazol-2-amine (5j). Yellow oil,
yield 66%, 1H NMR (300 MHz, CDCl3): δ 9.64 (s, 1H), 7.39–
7.17 (m, 9H), 6.63 (d, J = 8.22 Hz, 1H), 6.54 (s, 1H), 6.43 (d,
J = 8.22 Hz,1H), 5.89 (s, 2H), 5.34 (s, 2H). HRMS (EI): calcd
for C24H17O2N3Cl2: 449.0698, found: 449.0708.
N-(2 -chloro-6-fluorobenzylidene)-1-methyl-5-(3,4,5-trime-
thoxyphenyl)-1H-imidazol-2-amine (5k). Yellow solid, yield
32%, m.p. 148–151 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.56
(s, 1H), 7.35–7.30 (m, 2H), 7.26 (s, 2H), 7.10 (s, 2H),
3.91 (s, 9H), 3.79 (s, 3H). 13C NMR (75 MHz, CDCl3):
160.9, 153.8, 151.1, 138.4, 136.9, 134.7, 132.2, 126.9, 125.9,
123.0, 115.8, 106.1, 61.3, 56.6, 31.0. HRMS (EI): calcd for
C20H19O3N3ClF: 403.1099, found: 403.1105.
N-(2 -chloro -6 -fluorobenzylidene) -5 - (4 -chlorophenyl) -1
-ethyl-1H-imidazol-2-amine (5l). Yellow solid, yield 35%,
m.p. 117–119 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.57 (s,
1H), 7.45–7.26 (m, 6H), 7.11 (s, 2H), 4.26–4.19 (q, 2H),
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1.32 (t, J = 14.81, 7.32 Hz, 3H). HRMS (EI): calcd for
C18H14N3Cl2F: 361.0549, found: 361.0538.
N-(2 -chloro -6-fluorobenzylidene)-1-cyclopentyl-5-phenyl-
1H-imidazol-2-amine (5m). Yellow oil, yield 62%,
1 H NMR (300 MHz, CDCl3): δ 9.55 (s, 1H), 7.46–7.26
(m, 7H), 7.12–7.02 (m, 2H), 4.62–4.50 (m, 1H), 2.46–2.43
(m, 2H), 2.00–1.96 (m, 4H), 1.56–1.53 (m, 2H). 13C NMR
(75 MHz, CDCl3): 164.2, 160.8, 151.9, 137.1, 135.5, 132.1,
130.9, 129.0, 128.4, 126.9, 126.6, 123.2, 115.8, 57.5, 32.9,
25.1. HRMS (EI): calcd for C21H19N3ClF: 367.1252, found:
367.1244.
N-(2 -chloro -6-fluorobenzylidene)-1-(4-methoxybenzyl)-5-
phenyl-1H-imidazol-2-amine (5n). Yellow oil, yield 25%,
1H NMR (300 MHz, CDCl3): δ 9.62 (s, 1H), 7.37–7.26
(m, 8H), 7.14 (s, 1H), 6.93 (d, J = 8.22 Hz, 2H), 6.73 (d,
J = 8.22 Hz, 2H), 5.37 (s, 2H), 3.73 (s, 3H). 13C NMR
(75 MHz, CDCl3): 160.6, 158.7, 152.9, 150.6, 136.6, 134.1,
131.8, 129.8, 128.9, 128.1, 127.2, 126.3, 122.6, 115.4, 115.1,
113.8, 55.1, 45.9. HRMS (EI): calcd for C24H19ON3ClF:
419.1201, found: 419.12075.
N-(2,6 -difluorobenzylidene) -1 -pentyl -5 -phenyl -1H-imi-
dazol-2-amine (5o). Yellow solid, yield 60%, m.p. 37–
39 ◦C, 1H NMR (300 MHz, CDCl3): δ 9.47 (s, 1H), 7.46–
7.38 (m, 6H), 7.09 (s, 1H), 6.98 (t, J = 17.34, 8.22 Hz, 2H),
4.21 (t, J = 14.61, 7.29 Hz, 2H), 1.68–1.63 (m, 2H), 1.24–
1.17 (m, 4H), 0.80 (t, J = 13.68, 7.29 Hz, 3H). 13C NMR
(75 MHz, CDCl3): 164.2, 164.1, 160.7, 150.8, 149.3, 133.8,
132.3, 130.4, 128.7, 128.0, 126.9, 114.3, 114.2, 112.2, 112.1,
111.9, 43.2, 30.3, 28.6, 21.9, 13.8. HRMS (EI): calcd for
C21H21N3F2: 353.1704, found: 353.1707.
General procedure for the preparation of 4a–o. Imine
5(0.5 mmol) and mercapto acetic acid 3 (1 mmol) were suc-
cessively added to dry toluene (3 mL) in a 10-mL glass vial.
The resulting solution was irradiated at 120 ◦C ceiling tem-
perature for 30 min using a maximum 100 W microwave
power. After completion of the reaction, the reaction mix-
ture was diluted with 100 mL of ethyl acetate and washed
with NaHCO3 solution (50 mL×2), water (50 mL×2), and
brine (50 mL). The organic layer was dried over magnesium
sulfate, removed under reduced pressure and the residue was
purified by flash column chromatography (from 30 to 50%
ethyl acetate in heptane) to afford compounds 4a–o.
2-(2,6-Dichlorophenyl)-3-(1-methyl-5-phenyl-1H-imidazol-
2-yl)thiazolidin-4-one (4a). White solid, yield 15%, M.P.
188–190 ◦C, 1H NMR (300 MHz, DMSO-d6): δ 7.51–7.42
(m, 8H), 7.12 (s, 1H), 6.95 (s, 1H), 4.13 (s, 2H), 3.48 (s, 3H).
13C NMR (75 MHz, DMSO-d6): 171.6, 138.9, 135.2, 135.1,
133.1, 132.6, 131.5, 131.4, 129.5, 129.2, 128.2, 128.1, 125.6,
58.3, 33.6, 32.4. HRMS (EI): calcd for C19H15OSN3Cl2:
403.0313, found: 403.03439.
2- (2,6 -dichlorophenyl) -3 - (5 - (2,5 -dimethoxyphenyl) -1 -
methyl-1H-imidazol-2-yl)thiazolidin-4-one (4b). White
solid, yield 23%, m.p. 190–192 ◦C, 1H NMR (300 MHz,
DMSO-d6): δ 7.55–7.53 (d, J = 7.29, 1H), 7.46–7.36 (m, 2H),
7.08 (s, 1H), 7.00–6.97 (m, 2H), 6.76–6.74 (m, 2H), 4.10
(s, 2H), 3.71 (s, 3H), 3.60 (s, 3H), 3.23 (s, 3H). 13C NMR
(75 MHz, DMSO-d6): 171.4, 153.3, 151.1, 137.9, 135.3,
135.2, 132.4, 131.5, 131.3, 130.4, 129.1, 126.0, 118.9, 117.1,
115.5, 113.1, 58.3, 56.1, 55.8, 33.6, 31.6. HRMS (EI): calcd
for C21H19O3SN3Cl2: 463.0524, found: 463.05286.
2- (2,6 -Dichlorophenyl) -3 - (5 - (3,4 -dimethoxyphenyl) -1 -
methyl-1H-imidazol-2-yl)thiazolidin-4-one (4c). White
solid, yield 20%, m.p. 150–152 ◦C, 1H NMR (300 MHz,
DMSO-d6): δ 7.54–7.51 (d, J = 8.22, 1H), 7.43–7.37 (m,
2H), 7.12 (s, 1H), 6.99 (s, 1H), 6.93–6.88 (m, 3H), 4.13–
4.11 (d, J = 5.49, 2H), 3.77 (s, 6H), 3.46 (s, 3H). 13C NMR
(75 MHz, DMSO-d6): 171.6, 149.1, 149.0, 138.4, 135.2,
135.1, 133.2, 132.6, 131.5, 131.4, 129.2, 125.0, 121.9, 120.7,
112.2, 112.0, 58.2, 55.9, 33.6, 32.2. HRMS (EI): calcd for
C21H19O3SN3Cl2: 463.0524, found: 463.05043.
2- (2,6 -Dichlorophenyl) -3-(1-ethyl-5-phenyl-1H-imidazol-
2-yl)thiazolidin-4-one (4d). White solid, yield 21%, m.p.
172–175 ◦C, 1H NMR (300 MHz, DMSO-d6): δ 7.56–7.53
(d, J = 8.22, 1H), 7.44–7.37 (m, 7H), 7.06 (s, 1H), 6.92 (s,
1H), 4.14–4.13 (d, J = 3.66, 2H), 4.03–3.94 (m, 2H), 0.8–
0.75 (t, J = 13.71, 6.39, 3H). 13C NMR (75 MHz, DMSO-
d6): 172.2, 137.8, 135.6, 135.1, 132.5, 132.4, 131.7, 131.4,
130.0, 129.3, 129.1, 128.4, 128.0, 126.7, 58.4, 33.7, 15.5.
HRMS (EI): calcd for C20H17OSN3Cl2: 417.0469, found:
417.04416.
3- (5 - (4 -Bromophenyl) -1 -ethyl-1H-imidazol-2-yl)-2-(2,6-
dichlorophenyl)thiazolidin-4-one (4e). White solid, yield
37%, m.p. 147–150 ◦C, 1H NMR (300 MHz, DMSO-d6):
δ 7.63–7.61 (d, J = 7.32, 2H), 7.56–7.54 (d, J = 7.32, 1H),
7.44–7.38 (m, 4H), 7.07 (s, 1H), 6.98 (s, 1H), 4.15–4.13
(d, J = 4.56, 2H), 4.03–3.95 (m, 2H), 0.80–0.76 (t, J = 13.71,
6.42, 3H). 13C NMR (75 MHz, DMSO-d6): 172.2, 170.8,
138.2, 135.6, 135.1, 132.4, 131.7, 131.4, 131.2, 130.0, 129.2,
129.1, 127.2, 121.7, 58.4, 39.3, 33.7, 15.5. HRMS (EI): calcd
for C20H16OSN3BrCl2: 494.9574, found: 494.95768.
2- (2,6 -Dichlorophenyl) -3 - (1 -ethyl-5-(4-iodophenyl)-1H-
imidazol-2-yl)thiazolidin-4-one (4f). White solid, yield
63%, m.p. 190–193 ◦C, 1H NMR (300 MHz, DMSO-d6): δ
7.80–7.77 (d, J = 8.22, 2H), 7.56–7.53 (d, J = 7.32, 1H), 7.44–
7.34 (m, 2H), 7.25–7.22 (d, J = 8.22, 2H), 7.06 (s, 1H), 6.97
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(s, 1H), 4.15–4.13 (d, J = 4.56, 2H), 4.03–3.94 (m, 2H), 0.80–
0.75 (t, J = 13.71, 7.29, 3H). 13C NMR (75 MHz, DMSO-d6):
172.2, 138.1, 135.6, 135.1, 132.4, 131.7, 131.4, 129.9, 129.5,
129.1, 127.1, 94.7, 73.8, 58.4, 33.7, 15.5. HRMS (EI): calcd
for C20H16OSN3ICl2: 542.9436, found: 542.97441.
2- (2, 6 -Dichlorophenyl) -3 - (1 -methyl -5 - (4 - (methylthio)
phenyl)-1H-imidazol-2-yl)thiazolidin-4-one (4g). White
solid, yield 36%, m.p. 133–135 ◦C, 1H NMR (300 MHz,
DMSO-d6): δ 7.51 (s, 1H), 7.45–7.28 (m, 6H), 7.12 (s,
1H), 6.92 (s, 1H), 4.13–4.12 (d, J = 4.56, 2H), 3.47 (s, 3H).
13C NMR (75 MHz, DMSO-d6): 171.6, 138.9, 138.5, 135.2,
132.7, 132.6, 131.5, 131.4, 129.1, 128.5, 126.4, 125.8, 125.4,
58.2, 35.2, 33.6, 32.3, 31.6, 26.1, 22.4, 14.7. HRMS (EI):
calcd for C20H17OS2N3Cl2: 449.0190, found: 449.01921.
2- (2,6 -Dichlorophenyl) -3 - (1-ethyl-5-[1,1’-biphenyl]-1H-
imidazol-2-yl)thiazolidin-4-one (4h). White solid, yield
61%, m.p. 79–82 ◦C, 1H NMR (300 MHz, DMSO-d6): δ
7.76–7.69 (m, 4H), 7.69–7.38 (m, 8H), 7.09 (s, 1H), 7.00 (s,
1H), 4.16–4.15 (d, J = 3.66, 2H), 4.09–3.99 (m, 2H), 0.86–
0.81 (t, J = 13.71, 6.42, 3H). 13C NMR (75 MHz, DMSO-
d6): 172.2, 139.9, 139.6, 138.0, 135.6, 135.1, 132.0, 131.7,
131.4, 129.3, 129.1, 129.1, 128.4, 128.0, 127.5, 127.0, 126.9,
58.5, 33.7, 15.6. HRMS (EI): calcd for C26H21OSN3Cl2:
493.0782, found: 493.0785.
3- (1 -Butyl -5 -phenyl -1H- imidazol-2-yl)-2-(2,6-dichloro-
phenyl)thiazolidin-4-one (4i). White solid, yield 88%, m.p.
175–176 ◦C, 1H NMR (300 MHz, DMSO-d6): δ 7.57–7.54
(d, J = 7.32, 1H), 7.43–7.39 (m, 7H), 7.05 (s, 1H), 6.92 (s,
1H), 4.16–4.14 (d, J = 6.39, 2H), 3.95–3.86 (m, 2H), 1.15
(bs, 1H), 1.02–0.93 (m, 3H), 0.64–0.60 (t, J = 14.58, 7.29,
3H). 13C NMR (75 MHz, DMSO-d6): 172.2, 138.1, 135.7,
135.0, 132.7, 132.6, 131.6, 130.1, 129.3, 129.1, 128.4, 128.0,
126.6, 73.8, 58.4, 44.0, 33.8, 31.8, 19.3, 13.6. HRMS (EI):
calcd for C22H21OSN3Cl2: 445.0782, found: 445.07896.
3- (1-((Benzo[d][1,3]dioxol-5-yl)methyl)-5-phenyl-1H-imi-
dazol -2 -yl) -2 - (2,6-dichlorophenyl)-thiazolidin-4-one (4j).
White solid, yield 49%, m.p. 76–78 ◦C, 1H NMR (300 MHz,
DMSO-d6): δ 7.36–7.33 (m, 8H), 6.98 (s, 1H), 6.70–6.68
(d, J = 8.22, 1H), 6.41 (s, 1H), 6.23–6.20 (d, J = 7.32, 1H),
6.15 (s, 1H), 5.94 (s, 2H), 5.16–4.95 (q, 2H), 4.07 (s, 2H).
13C NMR (75 MHz, DMSO-d6): 172.3, 147.8, 146.7, 138.4,
134.4, 133.5, 131.3, 131.2, 130.7, 129.4, 128.8, 128.4, 126.4,
119.5, 108.6, 106.4, 101.3, 57.8, 47.1, 33.5. HRMS (EI):
calcd for C26H19O3SN3Cl2: 523.0524, found: 523.05242.
2- (2 - Chloro -6 - fluorophenyl) -3 - (5 - (3,4,5 - trimethoxy -
phenyl)-1-methyl-1H-imidazol-2-yl)- thiazolidin-4-one (4k).
White solid, yield 68%, m.p. 153–155 ◦C, 1H NMR
(300 MHz, DMSO-d6): δ 7.46–7.39 (m, 1H), 7.33 (bs,
2H), 6.94 (s, 1H), 6.79 (s, 1H), 6.65 (s, 2H), 4.08 (s,
2H), 3.80 (s, 6H), 3.67 (s, 3H), 3.46 (s, 3H). 13C NMR
(75 MHz, DMSO-d6): 171.4, 153.4, 138.8, 137.6, 133.2,
131.7, 125.5, 125.0, 105.7, 60.3, 56.3, 32.0. HRMS (EI):
calcd for C22H21O4SN3ClF: 477.0925, found: 477.09156.
2-(2-Chloro-6-fluorophenyl)-3-(5-(4-chlorophenyl)-1-ethyl-
1H-imidazol-2-yl)thiazolidin-4-one (4l). White solid,
yield 50%, m.p. 154–156 ◦C, 1H NMR (300 MHz, DMSO-
d6): δ 7.52–7.32 (m, 7H), 6.98 (s, 1H), 6.69 (s, 1H), 4.08 (bs,
2H), 4.00–3.92 (m, 2H), 0.84 (bs, 3H). 13C NMR (75 MHz,
DMSO-d6): 172.0, 138.2, 133.1, 132.0, 131.9, 131.2, 129.7,
129.3, 128.9, 127.1, 126.1, 57.3, 32.5, 15.3. HRMS (EI):
calcd for C20H16OSN3Cl2F: 435.0375, found: 435.03687.
2- (2 -Chloro -6 -fluorophenyl) -3 - (1 -cyclopentyl -5-phenyl
-1H-imidazol-2-yl)thiazolidin-4-one (4m). Yellow solid,
yield 32%, m.p. 45–47 ◦C, 1H NMR (300 MHz, DMSO-
d6): δ 7.41–7.30 (m, 8H), 6.74 (s, 1H), 6.60 (bs, 1H), 4.41
(bs, 1H), 4.03 (bs, 2H), 2.00 (bs, 1H), 1.75–1.21 (m, 8H).
13C NMR (75 MHz, DMSO-d6): 172.4, 133.2, 132.0, 131.9,
130.9, 130.7, 128.9, 128.7, 127.3, 125.9, 116.4, 116.2, 57.5,
56.9, 32.4, 32.1, 31.7, 24.6, 24.5. HRMS (EI): calcd for
C23H21OSN3ClF: 441.1078, found: 441.10795.
3- (1 - (4-Methoxybenzyl)-5-phenyl-1H-imidazol-2-yl)-2-(2-
chloro-6-fluorophenyl)thiazolidin-4-one (4n). Brown oil,
yield 24%, 1H NMR (300 MHz, DMSO-d6): δ 7.37–7.34
(m, 6H), 7.33–7.24 (d, J = 7.32, 1H), 7.14–7.08 (m, 1H),
6.98 (s, 1H), 6.76–6.55 (m, 4H), 5.96 (s, 1H), 5.16–4.98
(q, 2H), 3.99 (s, 2H), 3.67 (s, 3H). HRMS (EI): calcd for
C26H21O2SN3ClF: 493.1027, found: 493.10212.
2- (2,6 -Difluorophenyl)-3-(1-pentyl-5-phenyl-1H-imidazol-
2-yl)thiazolidin-4-one (4o). Light yellow solid, yield 26%,
m.p. 117–119 ◦C, 1H NMR (300 MHz, DMSO-d6): δ 7.46–
7.37 (m, 6H), 7.16–7.10 (t, J = 18.24, 10.05, 2H), 6.93 (s,
1H), 6.50 (s, 1H), 4.07–4.04 (d, J = 7.29, 2H), 3.93–3.85 (m,
1H), 3.81–3.73 (m, 1H), 1.21–1.18 (m, 1H), 0.99–0.92 (m,
5H), 0.68–0.63 (t, J = 14.61, 7.32, 3H). 13C NMR (75 MHz,
DMSO-d6): 171.9, 138.2, 132.7, 131.9, 130.1, 129.3, 128.4,
128.0, 126.5, 112.8, 112.5, 53.1, 44.28, 32.5, 28.9, 28.1,
21.6, 13.8. HRMS (EI): calcd for C23H23OSN3F2: 427.1530,
found: 427.15265.
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